Illumina, Inc. vs Marriott International Inc — how do they compare? Illumina, Inc. trades at $265 (market cap $40.43B), while Marriott International Inc trades at $360.95 (market cap $92.96B). The key difference: Marriott International Inc is far larger — about 2.3× Illumina, Inc.'s market cap, and Marriott International Inc pays a 0.82% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Marriott International Inc for 164 Days on average.
| ILMN | MAR | |
|---|---|---|
Market Cap | $40.43B | $92.96B |
Volume | 2,948,626 | 1,173,633 |
Sector | Health | Consumer Cyclical |
52-Week High | $293.69 | $402.54 |
52-Week Low | $91.00 | $259.04 |
Typical Hold Time | 83 Days | 164 Days |
Enterprise Value | $41.79B | $110.28B |
Dividend Yield | — | 0.82% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.
Marriott International (MAR) trades at $361.08, showing minimal daily movement with a slight decline of 0.06%. The stock maintains a bullish technical signal with strong moving average support and trades near key resistance at $360. Fundamentally, the company reported solid Q2 2026 earnings beat with $3.19 EPS versus $3.08 expected, continuing revenue growth to $26.19B in 2025, though valuation ratios remain elevated with P/E at 36.9. Recent developments include new technology partnerships and upcoming dividend payment.
Marriott presents a mixed investment case with strong operational performance offset by high valuation multiples. The consensus price target of $386.71 suggests 7% upside potential, supported by 44% analyst buy ratings. Key risks include rising debt levels with debt-to-asset ratio reaching 58.83% and potential travel sector volatility. The company's dominant market position and continued travel demand provide growth catalysts, but investors should weigh valuation concerns against fundamental strength.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →